GSK Relative Valuation
GSK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GSK is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.00
P/B
Median3y
Median5y
0.00
FCF Yield
Median3y
Median5y
Competitors Valuation Multiple
The average P/S ratio for GSK's competitors is 5.14, providing a benchmark for relative valuation. GSK plc Corp (GSK) exhibits a P/S ratio of 1.73, which is -66.39% above the industry average. Given its robust revenue growth of 4.04%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is GSK plc (GSK) currently overvalued or undervalued?
What is GSK plc (GSK) fair value?
How does GSK's valuation metrics compare to the industry average?
What is the current P/B ratio for GSK plc (GSK) as of Apr 27 2025?
What is the current FCF Yield for GSK plc (GSK) as of Apr 27 2025?
What is the current Forward P/E ratio for GSK plc (GSK) as of Apr 27 2025?